Immunogenic cell death: A new strategy to enhancing cancer immunotherapy

Immunogenic cell death (ICD) is a distinct type of stress-induced regulated cell death that can lead to adaptive immune responses and the establishment of immunological memory. ICD exhibits both similarities and differences when compared to apoptosis and other non-apoptotic forms of regulated cell d...

Full description

Saved in:
Bibliographic Details
Main Authors: Lei Dou, Yu Fang, Huiyuan Yang, Guo Ai, Na Shen
Format: Article
Language:English
Published: Taylor & Francis Group 2024-12-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
Online Access:https://www.tandfonline.com/doi/10.1080/21645515.2024.2437918
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850185273208471552
author Lei Dou
Yu Fang
Huiyuan Yang
Guo Ai
Na Shen
author_facet Lei Dou
Yu Fang
Huiyuan Yang
Guo Ai
Na Shen
author_sort Lei Dou
collection DOAJ
description Immunogenic cell death (ICD) is a distinct type of stress-induced regulated cell death that can lead to adaptive immune responses and the establishment of immunological memory. ICD exhibits both similarities and differences when compared to apoptosis and other non-apoptotic forms of regulated cell death (RCD). The interplay between ICD-mediated immunosurveillance against cancer and the ability of cancer cells to evade ICD influences the host-tumor immunological interaction. Consequently, the restoration of ICD and the development of effective strategies to induce ICD have emerged as crucial considerations in the treatment of cancer within the context of immunotherapy. To enhance comprehension of ICD in the setting of cancer, this paper examines the interconnected responsive pathways associated with ICD, the corresponding biomarkers indicative of ICD, and the mechanisms through which tumors subvert ICD. Additionally, this review explores strategies for reinstating ICD and the therapeutic potential of harnessing ICD in cancer immunotherapy.
format Article
id doaj-art-8e14c55b9fe147789f3eedc58b79e63e
institution OA Journals
issn 2164-5515
2164-554X
language English
publishDate 2024-12-01
publisher Taylor & Francis Group
record_format Article
series Human Vaccines & Immunotherapeutics
spelling doaj-art-8e14c55b9fe147789f3eedc58b79e63e2025-08-20T02:16:48ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2024-12-0120110.1080/21645515.2024.2437918Immunogenic cell death: A new strategy to enhancing cancer immunotherapyLei Dou0Yu Fang1Huiyuan Yang2Guo Ai3Na Shen4Department of Geriatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaIntensive Care Unit, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaDepartment of Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaDepartment of Pediatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaDepartment of Laboratory Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaImmunogenic cell death (ICD) is a distinct type of stress-induced regulated cell death that can lead to adaptive immune responses and the establishment of immunological memory. ICD exhibits both similarities and differences when compared to apoptosis and other non-apoptotic forms of regulated cell death (RCD). The interplay between ICD-mediated immunosurveillance against cancer and the ability of cancer cells to evade ICD influences the host-tumor immunological interaction. Consequently, the restoration of ICD and the development of effective strategies to induce ICD have emerged as crucial considerations in the treatment of cancer within the context of immunotherapy. To enhance comprehension of ICD in the setting of cancer, this paper examines the interconnected responsive pathways associated with ICD, the corresponding biomarkers indicative of ICD, and the mechanisms through which tumors subvert ICD. Additionally, this review explores strategies for reinstating ICD and the therapeutic potential of harnessing ICD in cancer immunotherapy.https://www.tandfonline.com/doi/10.1080/21645515.2024.2437918Cancerimmunogenic cell deathcell stressimmunotherapynanoparticle
spellingShingle Lei Dou
Yu Fang
Huiyuan Yang
Guo Ai
Na Shen
Immunogenic cell death: A new strategy to enhancing cancer immunotherapy
Human Vaccines & Immunotherapeutics
Cancer
immunogenic cell death
cell stress
immunotherapy
nanoparticle
title Immunogenic cell death: A new strategy to enhancing cancer immunotherapy
title_full Immunogenic cell death: A new strategy to enhancing cancer immunotherapy
title_fullStr Immunogenic cell death: A new strategy to enhancing cancer immunotherapy
title_full_unstemmed Immunogenic cell death: A new strategy to enhancing cancer immunotherapy
title_short Immunogenic cell death: A new strategy to enhancing cancer immunotherapy
title_sort immunogenic cell death a new strategy to enhancing cancer immunotherapy
topic Cancer
immunogenic cell death
cell stress
immunotherapy
nanoparticle
url https://www.tandfonline.com/doi/10.1080/21645515.2024.2437918
work_keys_str_mv AT leidou immunogeniccelldeathanewstrategytoenhancingcancerimmunotherapy
AT yufang immunogeniccelldeathanewstrategytoenhancingcancerimmunotherapy
AT huiyuanyang immunogeniccelldeathanewstrategytoenhancingcancerimmunotherapy
AT guoai immunogeniccelldeathanewstrategytoenhancingcancerimmunotherapy
AT nashen immunogeniccelldeathanewstrategytoenhancingcancerimmunotherapy